Autoimmune diseases represent a diverse group of chronic disorders in which the immune system mistakenly attacks healthy tissues, leading to sustained inflammation and organ dysfunction. Current therapeutic strategies such as corticosteroids, immunosuppressants, and biologics provide symptomatic relief but are often associated with systemic toxicity, limited selectivity, and increased risk of opportunistic infections. In recent years, nanotechnology has emerged as a promising approach to overcome these limitations by enabling the design of targeted nanoconstructs capable of site-specific drug delivery, controlled release, and improved therapeutic efficacy. Nanoconstructs such as liposomes, polymeric nanoparticles, dendrimers, micelles, and lipid-based carriers have demonstrated potential in modulating immune responses through precise delivery of immunomodulatory agents, peptides, or nucleic acids directly to affected tissues or immune cells. By incorporating ligands, antibodies, or peptides on their surfaces, these nanocarriers can selectively bind to disease-specific biomarkers, thus minimizing off-target effects. Furthermore, advances in computational modeling and molecular engineering have facilitated the optimization of nanoconstruct size, charge, and surface chemistry, enhancing biodistribution and cellular uptake. Several preclinical and early clinical studies highlight the effectiveness of nanoconstructs in autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, and type 1 diabetes. These systems not only enhance drug bioavailability but also enable immune tolerance restoration, offering a disease-modifying potential rather than symptomatic treatment alone. Despite these advances, translational barriers remain, including concerns about long-term safety, large-scale reproducibility, and regulatory approval. The integration of nanotechnology with artificial intelligence, biomarker discovery, and precision medicine could transform the therapeutic landscape for autoimmune disorders in the near future. This review systematically explores the role of targeted nanoconstructs in autoimmune disease treatment, evaluating current approaches, challenges, and future perspectives. Keywords: Parkinson’s disease, neurodegeneration, α-synuclein, Lewy bodies, dopaminergic neurons, motor symptoms, non-motor symptoms, herbal drugs, phytochemicals, oxidative stress, neuroprotection, alternative therapy.
Tabassum et al. (Fri,) studied this question.